- +46 18-56 64 00
Mr. Walldén has more than 20 years of executive management experience
and a record of achievements in the biotech and life science industries.
Until December 2008, he was President and CEO of Affibody Holding AB, which he restructured for near-term and sustained profitability. Prior to this, he was President and CEO of Biacore International AB, which, after a successful turnaround, was sold to GE Healthcare in 2006.
In 2000, Mr. Walldén led Pyrosequencing AB (now Biotage AB) through a successful IPO on OMX Stockholm. He has also been instrumental in establishing and growing companies such as PerSeptive Biosystems Inc. (now part of Life Technologies Inc.), Pharmacia Biosensor AB, and Pharmacia Biotech (both now part of GE Healthcare Life Sciences).
He serves on the boards of the Industrial Supervisory Board of Healthinvest Partners AB, Exiqon A/S, VisEn Medical Inc., Proxeon A/S, and Bergekullen Fastighets AB.
Mr. Walldén is a Chemical Engineer with studies in analytical chemistry and biochemistry at Uppsala University.